Synapse - Works

Results (5608)

Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study

Meeting Abstract

Necchi, A.; Joseph, R. W.; Loriot, Y.; Hoffman-Censits, J.; Perez Gracia, J. L.; Petrylak, D. P.; Zhu, Q.; Ding, B.; Kaiser, C.; Rosenberg, J. E.
Annals of Oncology (2017)

Fulltext@MSK | Save

Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer

Meeting Abstract

Naing, A.; Infante, J. R.; Wong, D. J.; Korn, M. W.; Aljumaily, R.; Papadopoulos, K.; Autio, K.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma

Meeting Abstract

Lee, C. H.; Makker, V.; Rasco, D.; Taylor, M.; Dutcus, C.; Shumaker, R.; Schmidt, E. V.; Stepan, D.; Li, D.; Motzer, R. J.
Annals of Oncology (2017)

Fulltext@MSK | Save

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups

Meeting Abstract

Escudier, B.; Tannir, N. M.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Plimack, E. R.; Barthelemy, P.; George, S.; Neiman, V.; Porta, C.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

Meeting Abstract

Grivas, P.; Plimack, E.; Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Bellmunt, J.; Powles, T.; Hahn, N.; de Wit, R.; Bajorin, D.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry

Meeting Abstract

Francini, E.; Yip, S.; Ahmed, N. S.; Li, H.; Ardolino, L.; Evan, C. P.; Kaymakcalan, M.; Shaw, G. K.; Kantoff, P.; Taplin, M. E.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)

Meeting Abstract

Hecht, J. R.; Naing, A.; Falchook, G.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J.; Autio, K.; Wainberg, Z. A.; Javle, M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

Meeting Abstract

de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Necchi, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Choueiri, T. K.; Hessel, C.; Halabi, S.; Sanford, B.; Hahn, O.; Michaelson, M. D.; Walsh, M.; Olencki, T.; Picus, J.; Small, E. J.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Chowdhury, S.; Abida, W.; Arija, J. A.; Daugaard, G.; Fizazi, K.; Gez, E.; Heidenreich, A.; Joly Lobbedez, F.; McDermott, R.; Merseburger, A. S.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save